Document Detail


Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension.
MedLine Citation:
PMID:  20026764     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Antagonism of vascular endothelial growth factor (VEGF) signaling by soluble fms-like tyrosine kinase 1 occurs during preeclampsia and is proposed to play an important role in the pathogenesis of preeclampsia. We reported recently that hypertension associated with chronic reductions in uteroplacental perfusion pressure (RUPP) is associated with increased soluble fms-like tyrosine kinase 1 and decreased free VEGF. Whether restoration of circulating VEGF can restore renal function and chronically decrease arterial pressure associated with placental ischemia remains unknown. We hypothesized that chronic infusion of VEGF(121) would attenuate hypertension, increase glomerular filtration rate, and reverse the endothelial dysfunction associated with chronic RUPP. VEGF(121) (at either 90 or 180 microg/kg per day) was administered for 5 days via osmotic minipump placed IP. Mean arterial pressure, renal function, and tissues were obtained on day 19 of pregnancy from RUPP+VEGF, RUPP, and normal pregnant dams. Mean arterial pressure was increased in the RUPP (131+/-3 mm Hg) compared with the normal pregnant (102+/-1 mm Hg) rats, and infusion of VEGF(121) resolved the hypertension (105+/-5 mm Hg). Glomerular filtration rate was decreased in the RUPP dams (1.5+/-0.3 mL/min) and restored to normal pregnant levels (3.1+/-0.5 mL/min) by VEGF(121) treatment (3.1+/-0.4 mL/min). Effective renal plasma flow, decreased by RUPP, was also increased by VEGF(121) infusion. Relaxation to acetylcholine was enhanced by the VEGF treatment (P<0.05). These data demonstrate that chronic infusion of VEGF(121) during late gestation restores glomerular filtration rate and endothelial function and reduces high blood pressure associated with placental ischemia. The present results suggest that VEGF(121) may be a candidate molecule for management of preeclampsia and its related complications.
Authors:
Jeffrey S Gilbert; Joseph Verzwyvelt; Drew Colson; Marietta Arany; S Ananth Karumanchi; Joey P Granger
Related Documents :
4703234 - Dynamics of glomerular ultrafiltration in the rat. iv. determination of the ultrafiltra...
6380364 - Pressure-fixation method of transferring cells from polycarbonate filters to glass slides.
2259084 - Adrenergic influences and interactions with angiotensin ii.
3746194 - Hydrostatic pressures in glomeruli and renal vasculature of the hagfish, eptatretus sto...
20658014 - Eustachian tube function in adults with intact tympanic membrane.
9146324 - Extracorporeal membrane oxygenation using a centrifugal pump and a servo regulator to p...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-12-21
Journal Detail:
Title:  Hypertension     Volume:  55     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-21     Completed Date:  2010-02-22     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  380-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Analysis of Variance
Animals
Blood Pressure / drug effects
Disease Models, Animal
Female
Glomerular Filtration Rate / drug effects
Hemodynamics / drug effects*,  physiology
Hypertension, Pregnancy-Induced / drug therapy*,  physiopathology
Infusions, Intravenous
Kidney Function Tests
Pregnancy
Pregnancy, Animal*
Probability
Random Allocation
Rats
Rats, Sprague-Dawley
Vascular Endothelial Growth Factor Receptor-1 / administration & dosage*
Grant Support
ID/Acronym/Agency:
F32 HL090269/HL/NHLBI NIH HHS; HL38499/HL/NHLBI NIH HHS; HL51971/HL/NHLBI NIH HHS; HL90269/HL/NHLBI NIH HHS; P01 HL051971/HL/NHLBI NIH HHS; P01 HL051971-165259/HL/NHLBI NIH HHS; //Howard Hughes Medical Institute
Chemical
Reg. No./Substance:
EC 2.7.10.1/Vascular Endothelial Growth Factor Receptor-1
Comments/Corrections
Comment In:
Hypertension. 2010 Feb;55(2):238-40   [PMID:  20026761 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neointimal hyperplasia and vasoreactivity are controlled by genetic elements on rat chromosome 3.
Next Document:  Blood pressure regulation in humans: calculation of an "error signal" in control of sympathetic nerv...